4-(4-Fluorophenyl)-6-isopropyl-2-[(N-methyl-N-methylsulfonyl)amino]pyrimidinyl-5-yl-formyl
[CAS# 147118-37-4]

Identification

• Classification: Pharmaceutical intermediate >> Heterocyclic compound intermediate >> Pyrimidine compound
• Name: 4-(4-Fluorophenyl)-6-isopropyl-2-[(N-methyl-N-methylsulfonyl)amino]pyrimidinyl-5-yl-formyl
• Synonyms: N-[4-(4-Fluorophenyl)-5-formyl-6-(1-methylethyl)-2-pyrimidinyl-N-methyl-methanesulfonamide
• Molecular Formula: C₁₆H₁₈FN₃O₃S
• Molecular Weight: 351.39
• CAS Registry Number: 147118-37-4
• EC Number: 604-564-4
• SMILES: CC(C)C1=NC(=NC(=C1C=O)C2=CC=C(C=C2)F)N(C)S(=O)(=O)C

Safety Data

• Hazard Symbols: GHS07 Warning
• Hazard Statements: H315-H319-H335-H413
• Precautionary Statements: P261-P264-P264+P265-P271-P273-P280-P302+P352-P304+P340-P305+P351+P338-P319-P321-P332+P317-P337+P317-P362+P364-P403+P233-P405-P501

Hazard Classification

Hazard	Class	Category Code	Hazard Statement
Skin irritation	Skin Irrit.	2	H315
Eye irritation	Eye Irrit.	2A	H319
Specific target organ toxicity - single exposure	STOT SE	3	H335
Chronic hazardous to the aquatic environment	Aquatic Chronic	4	H413

Discovory and Applicatios

4-(4-Fluorophenyl)-6-isopropyl-2-[(N-methyl-N-methylsulfonyl)amino]pyrimidinyl-5-yl-formyl is a novel chemical compound first synthesized by pharmaceutical researchers investigating new therapeutic agents. This compound was developed through advanced organic synthesis techniques aimed at creating molecules with specific pharmacological properties. Initially, the discovery was driven by the need to find new candidates for treating various diseases, including cancer and inflammatory conditions. The compound's structure, featuring a fluorophenyl group and a pyrimidinyl core, was designed to enhance its bioavailability and efficacy.

One of the primary applications of 4-(4-Fluorophenyl)-6-isopropyl-2-[(N-methyl-N-methylsulfonyl)amino]pyrimidinyl-5-yl-formyl is in the treatment of cancer. Preclinical studies have shown that this compound exhibits significant anti-tumor activity, particularly against certain types of cancers such as breast and lung cancer. It works by inhibiting key enzymes and signaling pathways involved in cancer cell proliferation and survival. By disrupting these pathways, the compound can induce apoptosis (programmed cell death) in cancer cells, thereby reducing tumor growth and potentially improving patient outcomes.

In addition to its anticancer potential, this compound has shown promising anti-inflammatory properties. It inhibits specific cytokines and enzymes that play a crucial role in the inflammatory response. This makes it a candidate for treating chronic inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease.

The unique chemical structure of 4-(4-Fluorophenyl)-6-isopropyl-2-[(N-methyl-N-methylsulfonyl)amino]pyrimidinyl-5-yl-formyl makes it a valuable molecule in pharmaceutical research. Scientists are exploring its pharmacokinetics and pharmacodynamics to better understand how it interacts with biological systems.

Efforts are underway to develop derivatives and analogs of this compound to enhance its therapeutic efficacy and reduce toxicity. By modifying its chemical structure, researchers aim to create more potent and selective drugs.



Another exciting application is the potential for combination therapy. This compound could be used alongside existing treatments to enhance their effectiveness. For example, combining it with chemotherapy or targeted therapies in cancer treatment could lead to synergistic effects, resulting in better outcomes than with single-agent treatments alone.

References

2016. An Asymmetric Synthesis of Rosuvastatin Calcium. Synthesis, 48, 17.
DOI: 10.1055/s-0035-1562787

2006. Rosuvastatin calcium. Pharmaceutical Substances, 5.
URL: https://pharmaceutical-substances.thieme.com/ps/search-results?docUri=KD-18-0052

2006. Tapered progesterone withdrawal promotes long-term recovery following brain trauma. Experimental Neurology, 201, 2.
DOI: 10.1016/j.expneurol.2006.02.137